Trial reportVeterinary parasitology2012
Antibody fusions reduce onset of experimental Cryptosporidium parvum infection in calves.
Trial report in Veterinary parasitology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 20 citations in OpenAlex.
- Calf Clinical Model of Cryptosporidiosis for Efficacy Evaluation of Therapeutics.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Unveiling genetic signatures associated with resilience to neonatal diarrhea in lambs through two GWAS approaches.Scientific reports · 2024Article
- Genomic and virulence analysis of in vitro cultured Cryptosporidium parvum.PLoS pathogens · 2024Article
- Pharmacokinetics and Pharmacodynamics of Clofazimine for Treatment of Cryptosporidiosis.Antimicrobial agents and chemotherapy · 2022Article
- Calf Clinical Model of Cryptosporidiosis for Efficacy Evaluation of Therapeutics.Methods in molecular biology (Clifton, N.J.) · 2020Article
- Impact of confinement housing on study end-points in the calf model of cryptosporidiosis.PLoS neglected tropical diseases · 2018Article
- Extended-spectrum antiprotozoal bumped kinase inhibitors: A review.Experimental parasitology · 2017Review
- Novel Bumped Kinase Inhibitors Are Safe and Effective Therapeutics in the Calf Clinical Model for Cryptosporidiosis.The Journal of infectious diseases · 2016Article
- The Thermodynamic Mechanism of Peptide-MHC Class II Complex Formation Is a Determinant of Susceptibility to HLA-DM.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Cryptosporidium parvum is one of the main causes of diarrhea in neonatal calves resulting in significant morbidity and economic losses for producers worldwide. We have previously demonstrated efficacy of a new class of antimicrobial antibody fusions in a neonatal mouse model for C. parvum infection. Here, we extend efficacy testing of these products to experimental infection in calves, the principal target species. Neonatal calves were challenged with C. parvum oocysts and concomitantly treated with antibody-biocide fusion 4H9-G1-LL37 over the course of four days. This resulted in reduced severity of the disease when compared to control animals. Overall clinical health parameters showed significant improvement in treated animals. Oocyst shedding was reduced in treated when compared to control animals. Control of oocyst shedding is a prerequisite for breaking the cycle of re-infection on dairy farms. Antibody-biocide fusion products thus have the potential to reduce the impact of the infection in both individual animals and in the herd.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.